Recent advances in delivery through the blood-brain barrier

Current Topics in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1148-1160

  Larsen, Jessica M ^a,b   Martin, Douglas R ^a,b   Byrne, Mark E ^a  

^a AUBURN UNIVERSITY   (United States)

^b Scott Ritchey Research Center College of Veterinary Medicine   (India)

Author keywords

Blood brain barrier; Carrier mediated delivery; Controlled drug delivery; Intravenous delivery; Nanocarriers; Nanoparticulate carriers

Indexed keywords

BI LIGAND LIPOSOME NANOCARRIER; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FC RECEPTOR; GOLD NANOPARTICLE; IMMUNOGLOBULIN G; INSULIN; INSULIN RECEPTOR; IRON OXIDE NANOPARTICLE; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; METAL NANOPARTICLE; NANOCARRIER; PEGYLATED LIPOSOME NANOCARRIER; POLY(DIMETHYLSILOXANE) (AKA DIMETHICONE); POLYACRYLIC ACID; POLYETHYLENE TEREPHTHALATE; POLYLACTIDE; POLYMER; SCAVENGER RECEPTOR B; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG CARRIER;

ARTICLE; BLOOD BRAIN BARRIER; CELL JUNCTION; DRUG DELIVERY SYSTEM; NONHUMAN; TRANSCYTOSIS; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; SYNTHESIS;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84903740461     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140329230311     Document Type: Article

References (121)

1. Barbu, E.; Molnàr, E.; Tsibouklis, J.; Górecki, D.C. The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin. Drug Deliv., 2009, 6, 553-565.
2. Björklund, A.; Lindvall, O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci., 2000, 3, 537-544.
3. Sondhi, D.; Johnson, L.; Purpura, K.; Monette, S.; Souweidane, M.M.; Kaplitt, M.G.; Kosofsky, B.; Yohay, K.; Ballon, D.; Dyke, J.; Kaminksy, S.M.; Hackett, N.R.; Crystal, R.G. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. Methods, 2012, 23, 324-335.
4. Sands, M.S.; Davidson, B.L. Gene therapy for lysosomal storage diseases. Mol. Ther., 2006, 13, 839-849.
5. Sands, M.S.; Haskins, M.E. CNS-directed gene therapy for lysosomal storage disease. Acta Paediatr., 2008, 97, 22-27.
6. Frank, R.T.; Aboody, K. S.; Najbauer, J. Strategies for enhancing antibody delivery to the brain. Biochim. Biophys. Acta, 2011, 1816, 191-198.
7. Bobo, R.H.; Laske, D.W.; Akbasak, A.; Morrison, P.F.; Dedrick, R.L.; Oldfield, E.H. Convection-enhanced delivery of macromole-cules in the brain. Proc. Natl. Acad. Sci. U. S. A, 1994, 91, 2076-2080.
8. Knight, K.H.; Brand, F.M.; Mchaourab, A.S.; Veneziano, G. Im-plantable intrathecal pumps for chronic pain: highlights and updates. Croat. Med. J., 2007, 48, 22-34.
9. Penn, R.D.; York, M.M.; Paice, J.A. Catheter implant systems for intrathecal drug delivery. J. Neurosurg., 1995, 83, 215-217.
10. Zhang, Y.; Miler, D.W. Pathways for Drug Delivery to the Central Nervous System. In Drug Delivery: Principles and Applications; Wang, B.; Siahaan, T.; Soltero, R., Eds.; John Wiley & Sons, Inc., 2005; pp. 29-53.
11. Dhuria, S.V; Hanson, L.R.; Frey II, W.H. Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations. J. Pharm. Sci., 2010, 99, 1654-1673.
12. Lochhead, J.J.; Thorne, R.G. Intranasal delivery of biologics to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64, 614-628.
13. Blanchette, M.; Michaud, K.; Fortin, D. A new method of quantitatively assessing the opening of the blood-brain barrier in murine animal models. J. Neurosci. Methods, 2012, 207, 125-129.
14. Stenehjem, D.D.; Hartz, A.M.S.; Bauer, B.; Anderson, G.W. Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier. Future Med. Chem., 2009, 1, 1623-1641.
15. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neuro-biol. Dis., 2004, 16, 1-13.
16. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7, 41-53.
17. Wang, P.P.; Frazier, J.; Brem, H. Local drug delivery to the brain. Adv. Drug Deliv. Rev., 2002, 54, 987-1013.
18. Abbott, N.J.; Patabendige, A. a K.; Dolman, D.E.M.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neu-robiol. Dis., 2010, 37, 13-25.
19. Rapoport, S.I. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell. Mol. Neuro-biol., 2000, 20, 217-230.
20. Rapoport, S.I. Blood - brain barrier in physiology and medicine; Raven Press: New York, 1976.
21. Betz, A.L.; Goldstein, G.W. Specialized Properties and Solute Transport in Brain Capillaries. Ann. Rev. Physiol., 1986, 48, 241-250.
22. D.D.; Silvestrini, B.; Cheng, C.Y.A.N.; Council, P.; York, N.; M, N. Y. D. D. Anchoring Junctions As Drug Targets: 2008, 60, 146-180.
23. Simionescu, M.; Simionescu, N.; Palade, G.E. Segmental Differentiations of Cell Junctions in the Vascular Endothelium: The Mi-crovasculature. J. Cell Biol., 1975, 67, 863-885.
24. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walker, P. Molecular Biology of the Cell; 4th ed.; Garland Science: New York, 2002.
25. Christ, G.J.; Spray, D.C.; El-Sabban, M.; Moore, L.K.; Brink, P.R. Gap Junctions in Vascular Tissues. Circ. Res., 1996, 631-646.
26. Pardridge, W.M. Drug Delivery to the Brain. J. Cereb. Blood Flow Metab., 1997, 713-731.
27. Hirschi, K.K.; D'Amore, P.A., Pericytes in the microvasculature. Cardiovasc. Res., 1996, 32, 687-698.
28. Armulik, A.; Genové, G.; Mäe, M.; Nisancioglu, M.H.; Wallgard, E.; Niaudet, C.; He, L.; Norlin, J.; Lindblom, P.; Strittmatter, K.; Johansson, B.R.; Betsholtz, C. Pericytes regulate the blood-brain barrier. Nature, 2010, 468, 557-561.
29. Dehouck, M.P.; Dehouck, B.; Fenart, L.; Cecchelli, R. Blood-Brain Barrier In Vitro: Rapid Evaluation of Strategies for Achieving Drug Targeting to the Central Nervous System. In Biology and Physiology of the Blood-Brain Barrier: Transport, Cellular Interactions, and Brain Pathologies; Couraud, P.-O.; Scherman, D., Eds.; Plenum Press: New York, 1996; pp. 143-145.
30. Krol, S. Challenges in drug delivery to the brain: nature is against us. J. Control. Release, 2012, 164, 145-155.
31. Davies, K.R.; Richardson, G.; Akmentin, W.; Acuff, V.; Fenster-macher, J.D. The Microarchitecture of Cerebral Vessels. In Biology and Physiology of the Blood-Brain Barrier: Transport, Cellular Interactions, and Brain Pathologies1; Couraud, P.-O.; Scherman, D., Eds.; Plenum Press: New York, 1996; pp. 83-90.
32. Pardridge, W.M. Peptide Drug Delivery to the Brain; 1st ed.; Raven Press, Ltd.: New York, 1991; pp. 1-357.
33. Tsuji, A.; Tamai, I. Blood-brain barrier transport of drugs. In Introduction to the Blood-Brain Barrier: Methodology, Biology, and Pa-thology2; Pardridge, W. M., Ed.; Cambridge University Press, 2006; pp. 238-245.
34. Silverberg, G.D.; Heit, G.; Huhn, S.; Jaffe, R.A.; Chang, S.D.; Bronte-Stewart, H.; Rubenstein, E.; Possin, K.; Saul, T.A. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology, 2001, 57, 1763-1766.
35. Miyan, J.A.; Nabiyouni, M.; Zendah, M. Development of the brain: a vital role for cerebrospinal fluid. Can. J. Physoilogy Pharmacol., 2003, 81, 317-328.
36. Laterra, J.; Keep, R.; Betz, L.A.; Goldstein, G.W. Blood-Cerebrospinal Fluid Barrier. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects; Lippincott-Raven: Philadelphia, 1999.
37. Saunders, N.R.; Dziegielewska, K.M. Brief Review: Barrier Mechanisms in the Brain, I. Adult Brain. Clin. Exp. Pharmacol. Physiol., 1998, 26, 11-19.
38. Veening, J.G.; Barendregt, H.P. The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid; a review. Cerebrospinal Fluid Res., 2010, 7, 1.
39. Laterra, J.; Keep, R.; Betz, L.A.; Goldstein, G.W. Blood-Cerebrospinal Fluid Barrier. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects; Lippincott-Raven: Philadelphia, 1999.
40. Cachón-González, M.B.; Wang, S.Z.; McNair, R.; Bradley, J.; Lunn, D.; Ziegler, R.; Cheng, S.H.; Cox, T.M. Gene transfer corrects acute GM2 gangliosidosis--potential therapeutic contribution of perivascular enzyme flow. Mol. Ther., 2012, 20, 1489-1500.
41. Baek, R.C.; Broekman, M.L.D.; Leroy, S.G.; Tierney, L. A; Sand-berg, M. A; D'Azzo, A.; Seyfried, T. N.; Sena-Esteves, M. AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One, 2010, 5, e13468.
42. Allard, E.; Passirani, C.; Benoit, J.-P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials, 2009, 30, 2302-2318.
43. Hitt, J.M.; de Leon-Casasola, O.A. Complications of intrathecal drug delivery systems. Tech. Reg. Anesth. Pain Manag., 2011, 15, 162-166.
44. Follett, K. A; Naumann, C.P. A prospective study of catheter-related complications of intrathecal drug delivery systems. J. Pain Symptom Manage., 2000, 19, 209-215.
45. Huynh, G.H.; Deen, D.F.; Szoka, F.C. Barriers to carrier mediated drug and gene delivery to brain tumors. J. Control. Release, 2006, 110, 236-259.
46. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12, 54-61.
47. Leamon, C.P. Receptor-Mediated Drug Delivery. In Drug Delivery: Principles and Applications; Wang, B.; Siahaan, T.; Soltero, R., Eds.; John Wiley & Sons, Inc., 2005; pp. 167-185.
48. Shier, D.; Butler, J.L.; Lewis, R. Hole's Human Anatomy and Physiology; McGraw-Hill Higher Education, 2004.
49. Gabathuler, R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis., 2010, 37, 48-57.
50. Chandra, D.; Karande, P. Transferrin mediated drug delivery to brain. Bioeng. Conf., 2011, 1-2.
51. Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab., 2012, 32, 1959-1972.
52. Coloma, M.J.; Lee, H.J.; Kurihara, A.; Landaw, E.M.; Boado, R.J.; Morrison, S.L.; Pardridge, W.M. Transport Across the Primate Blood- Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor. Pharm. Res., 2000, 17, 266-274.
53. Boado, R.J.; Zhang, Y.; Zhang, Y.; Pardridge, W.M. Humanization of Anti-Human Insulin Receptor Antibody for Drug Targeting Across the Human. Biotechnol. Bioeng., 2007, 96, 381-391.
54. Pardridge, W.M.; Boado, R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods in En-zymology, 2012, 503, 269-292.
55. Boado, R.J.; Zhang, Y.; Zhang, Y.; Wang, Y.; Pardridge, W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol. Bioeng., 2008, 100, 387-396.
56. Wang, D.; El-Amouri, S.S.; Dai, M.; Kuan, C.-Y.; Hui, D.Y.; Brady, R.O.; Pan, D. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc. Natl. Acad. Sci. U. S. A, 2013, 110, 2999-3004.
57. Sorrentino, N.C.; D'Orsi, L.; Sambri, I.; Nusco, E.; Monaco, C.; Spampanato, C.; Polishchuk, E.; Saccone, P.; De Leonibus, E.; Bal-labio, A.; Fraldi, A. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol. Med., 2013, 5(5), 675-690.
58. Pardridge, W.M. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J. Control. Release, 2007, 122, 345-348.
59. Ko, Y.T.; Bhattacharya, R.; Bickel, U. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release, 2009, 133, 230-237.
60. Pardridge, W.M. Gene Targeting In Vivo with Pegylated Immu-noliposomes. Methods Enzymol., 2003, 373, 507-528.
61. Pan, W.; Kastin, A.J.; Zankel, T.C.; van Kerkhof, P.; Terasaki, T.; Bu, G. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci., 2004, 117, 5071-5078.
62. Bellavance, M.-A.; Blanchette, M.; Fortin, D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J., 2008, 10, 166-177.
63. Blanchette, M.; Fortin, D. Chapter 23: Blood-Brain Barrier Disruption in the Treatment of Brain Tumors. In The Blood-Brain and Other Neural Barriers; Nag, S., Ed.; Humana Press: Totowa, NJ, 2011; Vol. 686, pp. 447-463.
64. Obata, Y.; Tajima, S.; Takeoka, S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J. Control. Release, 2010, 142, 267-276.
65. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A, 1996, 93, 14164-14169.
66. Zhang, Y.; Schlachetzki, F.; Pardridge, W. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther., 2003, 7, 11-18.
67. Lindqvist, A.; Rip, J.; Gaillard, P.J.; Björkman, S.; Hammarlund-Udenaes, M. Enhanced Brain Delivery of the Opioid Peptide DAMGO in Glutathione PEGylated Liposomes: A Microdialysis Study. Mol. Pharm., 2013, 10, 1533-1541.
68. Yang, H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res., 2010, 27, 1759-1771.
69. Immordino, M.L.; Dosio, F.; Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine, 2006, 1, 297-315.
70. Gatter, K.C.; Brown, G.; Trowbridge, I.S.; Woolston, R.E.; Mason, D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol., 1983, 36, 539-545.
71. Ponka, P.; Lok, C.N. The transferrin receptor: role in health and disease. Int. J. Biochem. Cell Biol., 1999, 31, 1111-1137.
72. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted Drug Delivery via the Transferrin Receptor-. 2002, 54, 561-587.
73. Abdalla, M.Y. Glutathione as Potential Target for Cancer Therapy; More or Less is Good? Jordan J. Biol. Sci., 2011, 4, 119-124.
74. Li, H.; Li, M.; Shih, W.Y.; Lelkes, P.I.; Shih, W.-H. Cytotoxicity Tests of Water Soluble ZnS and CdS Quantum Dots. J. Nanosci. Nanotechnol., 2011, 11, 3543-3551.
75. Duffin, R.; Tran, L.; Brown, D.; Stone, V.; Donaldson, K. Proin-flammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: highlighting the role of particle surface area and surface reactivity. Inhal. Toxicol., 2007, 19, 849-856.
76. Park, S.; Lee, Y.K.; Jung, M.; Kim, K.H.; Chung, N.; Ahn, E.-K.; Lim, Y.; Lee, K.-H. Cellular toxicity of various inhalable metal nanoparticles on human alveolar epithelial cells. Inhal. Toxicol., 2007, 19 Suppl 1, 59-65.
77. Sundaram, P.; Wower, J.; Byrne, M.E. A nanoscale drug delivery carrier using nucleic acid aptamers for extended release of therapeutic. Nanomedicine, 2012, 8, 1143-1151.
78. Sundaram, P.; Kurniawan, H.; Wower, J.; Byrne, M.E. Controlled and Extended Release of Daunomycin from DNA Aptamer-Programmed Gold Nanoparticles. Trans. Soc, Biomater., 2012, 35, 542.
79. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gürsoy, R.N.; Alonso, M.J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quiñoá, E.; Riguera, R.; Sargon, M.F.; Celik, H.H.; Demir, A.S.; Hincal, A.A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chi-tosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem., 2005, 16, 1503-1511.
80. Cole, A.J.; David, A.E.; Wang, J.; Galbán, C.J.; Yang, V.C. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials, 2011, 32, 6291-6301.
81. Etame, A.B.; Diaz, R.J.; O'Reilly, M.A.; Smith, C.A.; Mainprize, T.G.; Hynynen, K.; Rutka, J.T. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomedicine, 2012, 8, 1133-1142.
82. Chertok, B.; David, A.E.; Yang, V.C. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials, 2011, 32, 6245-6253.
83. Liu, H.-L.; Hua, M.-Y.; Yang, H.-W.; Huang, C.-Y.; Chu, P.-C; Wu, J.-S.; Tseng, I.-C; Wang, J.-J.; Yen, T.-C; Chen, P.-Y.; Wei, K.-C. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc. Natl. Acad. Sci. U. S. A, 2010, 107, 15205-15210.
84. Meng, F.; Zhong, Z.; Feijen, J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules, 2009, 10, 197-209.
85. Discher, D.E.; Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng., 2006, 8, 323-341.
86. Opsteen, J.; Cornelissen, J.; van Hest, J.C. Block copolymer vesicles. Pure Appl. Chem., 2004, 76, 1309-1319.
87. Meng, F.; Hiemstra, C; Engbers, G.H.M.; Feijen, J. Biodegradable Polymersomes. Macromolecules, 2003, 36, 3004-3006.
88. Onaca, O.; Enea, R.; Hughes, D.W.; Meier, W. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. Macro-mol. Biosci., 2009, 9, 129-139.
89. Lee, J.S.; Feijen, J. Polymersomes for drug delivery: design, formation and characterization. J. Control. Release, 2012, 161, 473-483.
90. U.S. Department of Health and Human Services Inactive Ingredient Search for Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
91. Ahmed, F.; Discher, D.E. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J. Control. Release, 2004, 96, 37-53.
92. Li, D.; Li, C; Wan, G.; Hou, W. Self-assembled vesicles of am-phiphilic poly(dimethylsiloxane)-b-poly(ethylene glycol) copolymers as nanotanks for hydrophobic drugs. Colloids Surfaces A Physicochem. Eng. Asp., 2010, 372, 1-8.
93. Rutnakornpituk, M.; Ngamdee, P.; Phinyocheep, P. Synthesis, characterization and properties of chitosan modified with polyethylene glycol)-polydimethylsiloxane amphiphilic block copolymers. Polymer. 2005, 46, 9742-9752.
94. Bakkour, Y.; Darcos, V.; Coumes, F.; Li, S.; Coudane, J. Brushlike amphiphilic copolymers based on polylactide and polyethylene glycol): Synthesis, self-assembly and evaluation as drug carrier. Polymer. 2013, 54, 1746-1754.
95. Chécot, F.; Lecommandoux, S.; Klok, H.; Gnanou, Y. From su-pramolecular polymersomes to stimuli-responsive nano-capsules based on poly(diene-b-peptide) diblock copolymers. Eur. Phys. J. E. Soft Matter, 2003, 10, 25-35.
96. Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release, 2008, 128, 120-127.
97. Pang, Z.; Gao, H.; Yu, Y.; Chen, J.; Guo, L.; Ren, J.; Wen, Z.; Su, J.; Jiang, X. Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes. Int. J. Pharm., 2011, 415, 284-292.
98. Gan, C.W.; Feng, S.-S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials, 2010, 31, 7748-7757.
99. Stojanov, K.; Georgieva, J.V.; Brinkhuis, R.P.; van Hest, J.C; Rutjes, F.P.; Dierckx, R.A.J.O.; de Vries, E.F.J.; Zunhorn, I.S. In vivo biodistribution of prion-and GM1-targeted polymersomes following intravenous administration in mice. Mol. Pharm., 2012, 9, 1620-1627.
100. Popescu, M.-T.; Tsitsilianis, C. Controlled Delivery of Functional-ized Gold Nanoparticles by pH-Sensitive Polymersomes. ACS Macro Lett., 2013, 2, 222-225.
101. Abbott, N.J. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J. Inherit. Metab. Dis., 2013, 36, 437-449.
102. Johanson, C.E.; Stopa, E.G.; McMillan, P.N. The Blood-Cerebrospinal Fluid Barrier: Structure and Functional Significance. In The Blood-Brain and Other Neural Barriers; Nag, S., Ed.; Humana Press: Totowa, NJ, 2011; Vol. 686, pp. 101-131.
103. Betanzos, A.; Nava, P.; Jaramillo, B.E.; Gonz, L. Tight junction proteins. Prog. Biophys. Mol. Biol. 2003, 81, 1-44.
104. Huber, O. Structure and function of desmosomal proteins and their role in development and disease. Cell. Mol. Life Sci., 2003, 60, 1872-1890.
105. Sorensson, J. Glomerular Endothelial Fenestrae In Vivo Are Not Formed from Caveolae. J. Am. Soc. Nephrol., 2002, 13, 2639-2647.
106. Tkachenko, E.; Tse, D.; Sideleva, O.; Deharvengt, S.J.; Luciano, M.R.; Xu, Y.; McGarry, C.L.; Chidlow, J.; Pilch, P.F.; Sessa, W.C.; Toomre, D.K.; Stan, R.V. Caveolae, fenestrae and transen-dothelial channels retain PV1 on the surface of endothelial cells. PLoS One, 2012, 7, e32655.
107. Dermietzel, R.; Traub, O.; Hwang, T.K.; Beyer, E.; Bennett, M.V; Spray, D.C.; Willecke, K. Differential expression of three gap junction proteins in developing and mature brain tissues. Proc. Natl. Acad. Sci. U. S. A, 1989, 86, 10148-10152.
108. Fauci, A.; Braunwald, E.; Isselbacher, K.; Wilson, J.; Marin, J.; Kasper, D.; Hauser, S.; Longo, D. Harrison's principles of internal medicine; 14th ed.; McGraw-Hill Health Professions Division: New York, 1998; pp. A2-A8.
109. Bickel, U. Intravenous Injection/Pharmacokinetics. In Introduction to the Blood-Brain Barrier: Methodology, Biology, and Pathology; Pardridge, W. M., Ed.; Cambridge University Press, 2006; pp. 41-47.
110. Bickel, U.; Yoshikawa, T.; Pardridge, W. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001, 46, 247-279.
111. Haselbacher, G.K.; Schwab, M.E.; Pasi, A.; Humbel, R.E. Insulinlike growth factor II (IGF II) in human brain: regional distribution of IGF II and of higher molecular mass forms. Proc. Natl. Acad. Sci. U. S. A, 1985, 82, 2153-2157.
112. Acerini, C.L.; Clayton, K.L.; Hintz, R.; Baker, B.; Watts, A.; Holly, J.M.; Dunger, D.B. Serum insulin-like growth factor II levels in normal adolescents and those with insulin dependent diabetes mellitus. Clin. Endocrinol. (Oxf). 1996, 45, 13-19.
113. Golden, P. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest., 1997, 99, 14-18.
114. Klein, S.; Coppack, S.W.; Mohamed-Ali, V.; Landt, M. Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes, 1996, 45, 984-987.
115. Considine, R.V; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; McKee, L.J.; Bauer, T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med., 1996, 334, 292-295.
116. Mankarious, S.; Lee, M.; Fischer, S.; Pyun, K.; Ochs, H.; Oxelius, V.; Wedgwood, R. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered. J. Lab. Clin. Med., 1988, 112, 634-640.
117. McNeeley, K.M.; Annapragada, A.; Bellamkonda, R.V Decreased circulation time offsets increased efficacy of PEGylated nanocarri-ers targeting folate receptors of glioma. Nanotechnology, 2007, 18, 385101.
118. McNeeley, K.M.; Karathanasis, E.; Annapragada, A.V; Bellamkonda, R.V. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials, 2009, 30, 3986-3995.
119. Sharma, G.; Modgil, A.; Layek, B.; Arora, K.; Sun, C.; Law, B.; Singh, J. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection. J. Control. Release, 2013, 167, 1-10.
120. Prades, R.; Guerrero, S.; Araya, E.; Molina, C.; Salas, E.; Zurita, E.; Selva, J.; Egea, G.; López-Iglesias, C.; Teixidó, M.; Kogan, M. J.; Giralt, E. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Bioma-terials, 2012, 33, 7194-7205.
121. Hu, K.; Li, J.; Shen, Y.; Lu, W.; Gao, X.; Zhang, Q.; Jiang, X. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release, 2009, 134, 55-61.